GlassScriptPhysician profile
David J Altman
NPI 1598764433
$22,998.76
in general payments reported to CMS, 2019-2025
30 companies · $3,650 in 2025
The $3,650 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,491 · 2020: $1,269 · 2021: $2,357 · 2022: $3,238 · 2023: $3,372 · 2024: $3,621 · 2025: $3,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,101.42 |
| Education | $541.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $3,928.90 | 2019-2025 | Siliq, Targretin, Duobrii |
| Janssen Biotech, INC. | $3,919.32 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $3,061.55 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Ucb, INC. | $1,696.55 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,423.98 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,042.39 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $1,039.61 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $865.36 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $790.01 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $761.22 | 2022-2025 | Sotyktu |
| Amgen INC. | $751.32 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $746.51 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $580.86 | 2019-2025 | Adbry |
| Galderma Laboratories, L.P. | $561.84 | 2019-2025 | Nemluvio, Aklief |
| Pfizer INC. | $470.70 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $220.26 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $210.27 | 2023-2024 | Vtama |
| Prugen, INC. Pharmaceuticals | $135.71 | 2019-2020 | |
| Almirall LLC | $121.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $121.56 | 2021-2023 | |
| Celgene Corporation | $108.29 | 2019 | |
| Mayne Pharma Commercial LLC | $77.79 | 2019 | |
| Sandoz INC. | $77.74 | 2019-2020 | |
| Dermira, INC. | $76.62 | 2019-2020 | |
| Organon LLC | $61.16 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $60.46 | 2021 | |
| Mallinckrodt Hospital Products INC. | $28.49 | 2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.79 | 2022 | |
| Verrica Pharmaceuticals INC. | $18.11 | 2024 | Ycanth |
| Taro Pharmaceuticals USA, INC. | $15.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Altman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.